Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings or view top-rated stocks.

15 Wall Street analysts have issued 1 year target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $54.00 to $106.00. On average, they anticipate the company's share price to reach $77.93 in the next twelve months. This suggests a possible upside of 65.0% from the stock's current price.
View analysts price targets for APLS or view top-rated stocks among Wall Street analysts.

Apellis Pharmaceuticals' stock was trading at $59.86 at the beginning of 2024. Since then, APLS stock has decreased by 21.1% and is now trading at $47.22.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our APLS earnings forecast.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its earnings results on Tuesday, February, 27th. The company reported ($0.73) EPS for the quarter, hitting the consensus estimate of ($0.73). The firm earned $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative trailing twelve-month return on equity of 178.60%. The firm's revenue was up 545.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.50) EPS.

ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Jacob Forward ETF (JFWD), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).ProShares Ultra Nasdaq Biotechnology (BIB).

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

Apellis Pharmaceuticals (APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Apellis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.10%), Hennion & Walsh Asset Management Inc. (0.01%), Handelsinvest Investeringsforvaltning (0.00%), Future Financial Wealth Managment LLC (0.00%) and Portman Square Capital LLP (0.00%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Caroline Baumal, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends.

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.